Hit or Miss? The Importance of Triage in the Active to Hit Transition

Time: To be announced
To be announced
 Alexandra Stowell


When we discuss hit finding as part of the drug discovery process, HTS, Fragment Screening and vHTS are often words that will arise. Hit finding is often thought of in terms of screening the compounds themselves, in whichever way is deemed most appropriate for any given target. But the output from that screen, is not the Hit…That’s just the start of the process. At Sygnature Discovery, we have been working to ensure that the transition from a compound that is selected from the screen as an ‘Active’ , is triaged in a thorough way, to assess technology artefacts, contaminants, non-specific binding and solubility through both chemistry and biology assessment, and be confirmed as a Hit. Using recent data, I will outline the process Sygnature employ to build confidence in screening output and move compounds to the next stage of drug discovery.
To view the video assoicated with this lecture click here

Hosted By


The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Web Site Find us on Facebook Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2022